TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37229174

Group type: EXPERIMENTAL
Intervention: Casirivimab plus Imdevimab (CAS + IMD)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 37229650

Group type: EXPERIMENTAL
Intervention: Baricitinib (BARI) 4 mg/day for 52 weeks
Number of subjects: 30
Study: 37229775

Group type: EXPERIMENTAL
Intervention: 6 mg of elemental oral iron (18.6 mg ferrous sulphate) twice daily for 8 weeks
Number of subjects: 36
Study: 37229879

Group type: EXPERIMENTAL
Intervention: Carboplatin dosing based on Jelliffe formula
Number of subjects: 3830

Group type: EXPERIMENTAL
Intervention: Carboplatin dosing based on MDRD and Cockcroft-Gault formulas
Number of subjects: 3830

Group type: EXPERIMENTAL
Intervention: NCCN guidelines for estimating renal function
Number of subjects: 3830
Study: 37230101

Group type: EXPERIMENTAL
Intervention: Supplemental dolutegravir (50 mg 12 h later)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo (matched placebo 12 h later)
Number of subjects: 108
Study: 37230105

Group type: EXPERIMENTAL
Intervention: Point-of-care CRP testing plus routine care
Number of subjects: 39856

Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 39856

Group type: EXPERIMENTAL
Intervention: Point-of-care CRP testing plus routine care (per-protocol analysis)
Number of subjects: 39856
Study: 37230168

Group type: EXPERIMENTAL
Intervention: Integrated contingency management with stepped care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 37230366

Group type: EXPERIMENTAL
Intervention: Continuous upadacitinib 30 mg
Number of subjects: 484

Group type: COMPARATOR
Intervention: Switching from dupilumab to upadacitinib 30 mg
Number of subjects: 484
Study: 37230383

Group type: EXPERIMENTAL
Intervention: Approach A (data-driven, hypothesis-free)
Number of subjects: 6720

Group type: EXPERIMENTAL
Intervention: Approach B (unsupervised Random Forest guided by clinical input)
Number of subjects: 6720

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 6720
Study: 37230499

Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg) + Mycophenolate mofetil (2 g daily)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo + Mycophenolate mofetil (2 g daily)
Number of subjects: 122
Study: 37230515

Group type: EXPERIMENTAL
Intervention: Carbon dioxide flooding of the surgical field
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no carbon dioxide flooding)
Number of subjects: 80
Study: 37230521

Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37230524

Group type: EXPERIMENTAL
Intervention: One oral loading dose of 100,000 IU vitamin D
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37230523

Group type: COMPARATOR
Intervention: Standard care with 0 sessions of HBOT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard care with 20 sessions of HBOT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard care with 30 sessions of HBOT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard care with at least 40 sessions of HBOT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study: 37230752

Group type: EXPERIMENTAL
Intervention: Agricultural, animal husbandry worker (ISCO: 6-2)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Salesman (ISCO: 4-51)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Electrical fitters and related, electrical and electronics workers employed for 2 years or more (ISCO: 8-5)
Number of subjects: 454
Study: 37230851

Group type: EXPERIMENTAL
Intervention: Diet rich in fruit and vegetables (measured by carotene plasma concentrations)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Total carotene
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: α-carotene
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: β-carotene
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: β-carotene and total carotene
Number of subjects: 204
Study: 37230961

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 48832

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 48832
Study: 37231074

Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 917

Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 917

Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 917

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 917
Study: 37231080

Group type: EXPERIMENTAL
Intervention: Mescaline 500 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: LSD 100 µg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Psilocybin 20 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mescaline 300 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mescaline and LSD
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: None of the substances
Number of subjects: 32
Study: 37231094

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37231221

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 64
Study: 37231296

Group type: EXPERIMENTAL
Intervention: Nirmatrelvir with ritonavir (PAXLOVID™)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nirmatrelvir without ritonavir (control)
Number of subjects: 0
Study: 37231350

Group type: EXPERIMENTAL
Intervention: Lu AG09222 + PACAP38 infusion
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo + PACAP38 infusion
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lu AG09222
Number of subjects: 25
Study: 37231386

Group type: EXPERIMENTAL
Intervention: Supported self-management (SSM)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Spinal manipulation therapy (SMT)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Both SSM and SMT
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Medical care
Number of subjects: 1000
Study: 37231390

Group type: EXPERIMENTAL
Intervention: Personalized rTMS synchronized to the trough of the sensorimotor µ-oscillation
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard rTMS (non-synchronized)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Sham rTMS (ineffective rTMS)
Number of subjects: 144
Study: 37231445

Group type: EXPERIMENTAL
Intervention: Short-term exposure to ambient fine particulate matter (PM ≤ 2.5 µm)
Number of subjects: 10142

Group type: EXPERIMENTAL
Intervention: Long-term exposure to ambient fine particulate matter (PM ≤ 2.5 µm)
Number of subjects: 10142
Study: 37231477

Group type: EXPERIMENTAL
Intervention: mHealth application for ORL patients and caregivers during the perioperative period
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard care (oral information and brochures)
Number of subjects: 180
Study: 37231479

Group type: EXPERIMENTAL
Intervention: Pre-release extended-release naltrexone (XR-NTX) + referral to community XR-NTX
Number of subjects: 0

Group type: COMPARATOR
Intervention: Referral only
Number of subjects: 0
Study: 37231634

Group type: EXPERIMENTAL
Intervention: Intelligent physical exercise training (IPET) for 1 hour weekly during paid working hours for 2 years, plus recommendations for 30-minute leisure time physical activity 6 days/week (LPA)
Number of subjects: 387

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 387
Study: 37231670

Group type: EXPERIMENTAL
Intervention: CT-P47 (162 mg/0.9 mL, single subcutaneous dose)
Number of subjects: 289

Group type: COMPARATOR
Intervention: EU-tocilizumab (single subcutaneous dose)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: CT-P47
Number of subjects: 289

Group type: COMPARATOR
Intervention: EU-tocilizumab
Number of subjects: 289
Study: 37231682

Group type: EXPERIMENTAL
Intervention: BGC balloon inflation during EVT
Number of subjects: 124

Group type: COMPARATOR
Intervention: No balloon inflation during EVT
Number of subjects: 124
Study: 37231838

Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 0
Study: 37231977

Group type: EXPERIMENTAL
Intervention: DPA duration variability
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: DPA performance variability
Number of subjects: 126
Study: 37232002

Group type: EXPERIMENTAL
Intervention: Asenapine (10 or 20 mg/day)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 37232058

Group type: EXPERIMENTAL
Intervention: BI 685509
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37232393

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 613

Group type: COMPARATOR
Intervention: Non-statin therapy
Number of subjects: 613
Study: 37232425

Group type: EXPERIMENTAL
Intervention: HD-IVUS-guided primary PCI
Number of subjects: 200
Study: 37232430

Group type: EXPERIMENTAL
Intervention: ccIIV4
Number of subjects: 230

Group type: COMPARATOR
Intervention: LAIV4
Number of subjects: 230
Study: 37232493

Group type: EXPERIMENTAL
Intervention: At-home HPV self-sampling kits
Number of subjects: 233
Study: 37232534

Group type: EXPERIMENTAL
Intervention: Self-management strategies and medications (prescription and over-the-counter)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Healthcare provider assessment and support
Number of subjects: 11
Study: 37232853

Group type: EXPERIMENTAL
Intervention: Finger cuff system (ClearSight; Edward Lifesciences)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Upper arm measurements
Number of subjects: 130

Group type: COMPARATOR
Intervention: Lower leg measurements
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Post-cardiovascular intervention measurements at all sites
Number of subjects: 130
Study: 37232940

Group type: EXPERIMENTAL
Intervention: Single dose 10 mg/kg of L-AmB
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 10 mg/kg of L-AmB on D1, and 5 mg/kg of L-AmB on D3
Number of subjects: 118

Group type: COMPARATOR
Intervention: 3 mg/kg of L-AmB daily for 2 weeks (control)
Number of subjects: 118
Study: 37233207

Group type: EXPERIMENTAL
Intervention: cTACE
Number of subjects: 28
Study: 37233785

Group type: EXPERIMENTAL
Intervention: PET agent A
Number of subjects: 50

Group type: COMPARATOR
Intervention: PET agent B
Number of subjects: 50
Study: 37233882

Group type: EXPERIMENTAL
Intervention: Low plasma adropin concentrations
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Adropin tertiles (1st to 3rd)
Number of subjects: 452
Study: 37233888

Group type: EXPERIMENTAL
Intervention: ICC-T (Interaction Competencies with Children-for Teachers)
Number of subjects: 173

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 173
Study: 37233897

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 37233987

Group type: EXPERIMENTAL
Intervention: Docetaxel plus Trametinib
Number of subjects: 53
Study: 37234006

Group type: EXPERIMENTAL
Intervention: Music Therapy (MT) in NICU
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Music Therapy (MT) postdischarge
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Interaction of MT in NICU and MT postdischarge
Number of subjects: 206
Study: 37234014

Group type: EXPERIMENTAL
Intervention: Free medicine distribution (access to 128 medicines with no out-of-pocket costs for 3 years)
Number of subjects: 747

Group type: COMPARATOR
Intervention: Usual medicine access
Number of subjects: 747
Study: 37234760

Group type: EXPERIMENTAL
Intervention: Motivational interviewing counseling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automated text messages and quiz questions about HIV management (21 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Financial rewards for viral suppression (lottery prize vs. fixed compensation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Viral suppression
Number of subjects: 0
Study: 37235505

Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts
Number of subjects: 1988

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Number of subjects: 1988

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 1988

Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate
Number of subjects: 1988

Group type: COMPARATOR
Intervention: Control group (no stimulant exposure)
Number of subjects: 1988
Study: 37235629

Group type: EXPERIMENTAL
Intervention: Disease-invaded lung tissue
Number of subjects: 23

Group type: COMPARATOR
Intervention: Non-invaded lung tissue
Number of subjects: 23
Study: 37235690

Group type: EXPERIMENTAL
Intervention: Natalizumab plus corticosteroids
Number of subjects: 75

Group type: COMPARATOR
Intervention: Corticosteroids alone (Control)
Number of subjects: 75
Study: 37235836

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 37235845

Group type: EXPERIMENTAL
Intervention: Whole-body PET-CT
Number of subjects: 369

Group type: COMPARATOR
Intervention: Conventional staging
Number of subjects: 369
Study: 37235976

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 345

Group type: COMPARATOR
Intervention: Chemotherapy (Cisplatin plus Pemetrexed)
Number of subjects: 345
Study: 37236007

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy with agalsidase beta
Number of subjects: 8000
Study: 37236033

Group type: EXPERIMENTAL
Intervention: Adavosertib 225 mg BID orally for 2.5 days and carboplatin AUC 5 mg/ml·min intravenously
Number of subjects: 32
Study: 37236221

Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine plus tafenoquine (300 mg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: dihydroartemisinin-piperaquine alone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: primaquine (15 mg) plus dihydroartemisinin-piperaquine
Number of subjects: 150
Study: 37236246

Group type: EXPERIMENTAL
Intervention: Novel therapeutic intervention over 48 weeks
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Baseline fatigue
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Baseline HRQoL
Number of subjects: 173
Study: 37236398

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily for up to 3 years
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 680

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 680
Study: 37236549

Group type: COMPARATOR
Intervention: Standardized low-fat diet
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Personalized diet
Number of subjects: 156
Study: 37236636

Group type: EXPERIMENTAL
Intervention: M9241 at 4, 8, 12, or 16.8 µg/kg every 4 weeks plus avelumab 10 mg/kg every 2 weeks (dose levels 1-4)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: M9241 16.8 µg/kg every 4 weeks plus avelumab 800 mg once a week for 12 weeks followed by every 2 weeks (DL5/dose expansion)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: M9241 plus avelumab (all dose levels)
Number of subjects: 52
Study: 37236666

Group type: EXPERIMENTAL
Intervention: Prophylactic single dose of fibrinogen, in addition to standard of care
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard of care without study medication prior to skin incision
Number of subjects: 32
Study: 37236706

Group type: EXPERIMENTAL
Intervention: Pre-radiation therapy (RT) characteristics
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Time between extraction and start of RT
Number of subjects: 572
Study: 37236829

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 201
Study: 37236877

Group type: EXPERIMENTAL
Intervention: Beeswax
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study: 37236899

Group type: EXPERIMENTAL
Intervention: Pilocarpine microneedle patches
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ionotophoresis
Number of subjects: 50
Study: 37236995

Group type: EXPERIMENTAL
Intervention: PTX-COVID19-B vaccine (16-µg, 40-µg, or 100-µg doses)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PTX-COVID19-B vaccine (all doses)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PTX-COVID19-B vaccine (40-µg dose)
Number of subjects: 60
Study: 37237172

Group type: EXPERIMENTAL
Intervention: GSK3368715 (50, 100, and 200 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: GSK3368715 (100 mg)
Number of subjects: 31
Study: 37237266

Group type: EXPERIMENTAL
Intervention: Adipsin overexpression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adipsin-enriched exosomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adipsin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Csk knockdown
Number of subjects: 0
Study: 37237278

Group type: EXPERIMENTAL
Intervention: Dual-task gait analysis using foot-worn inertial sensors
Number of subjects: 29

Group type: COMPARATOR
Intervention: Single-task gait metrics
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Dual-task effect on gait speed
Number of subjects: 29
Study: 37237302

Group type: EXPERIMENTAL
Intervention: Team-focused implementation strategies (n = 2 CACs)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Standard implementation (n = 2 CACs)
Number of subjects: 4
Study: 37237339

Group type: EXPERIMENTAL
Intervention: Public-facing, tailored health communication intervention (LungTalk) via social media
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37237405

Group type: EXPERIMENTAL
Intervention: Low hemoglobin at baseline (n=224)
Number of subjects: 1114

Group type: COMPARATOR
Intervention: Normal hemoglobin at baseline (n=890)
Number of subjects: 1114
Study: 37237416

Group type: EXPERIMENTAL
Intervention: Metreleptin, a recombinant analog of human leptin, administered as an adjunct to diet.
Number of subjects: 85
Study: 37237425

Group type: EXPERIMENTAL
Intervention: DeSSBack (electronic clinical decision support system)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 36
Study: 37239618

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (20 g of whey protein isolate) with resistance training (RT) for 12 weeks, twice a week.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group received an isocaloric drink (20 g of maltodextrin) with resistance training (RT) for 12 weeks, twice a week.
Number of subjects: 26
Study: 37239720

Group type: EXPERIMENTAL
Intervention: Mobile application (LactApp) used in addition to usual clinical practice.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual clinical practice (control group).
Number of subjects: 0
Study: 37240667

Group type: EXPERIMENTAL
Intervention: Complete response (UAS7 = 0)
Number of subjects: 382

Group type: COMPARATOR
Intervention: UAS7 = 1-6 evaluations
Number of subjects: 382
Study: 37242129

Group type: EXPERIMENTAL
Intervention: Aversive conditioning (lipid infusion via naso-duodenal catheter)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham conditioning (sham infusion)
Number of subjects: 12
Study: 37242222

Group type: EXPERIMENTAL
Intervention: Infants fed formula supplemented with 0.2 g/L 2'-FL + 2.2 g/L GOS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infants fed formula supplemented with 1.0 g/L 2'-FL + 1.4 g/L GOS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breastfed infants
Number of subjects: 0
Study: 37242723

Group type: EXPERIMENTAL
Intervention: Immediate-release tacrolimus (TAC-IR)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Extended-release tacrolimus (TAC-LCP)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Whole blood tacrolimus concentrations
Number of subjects: 23

Group type: COMPARATOR
Intervention: Calcineurin activity (CNA)
Number of subjects: 23
Study: 37243171

Group type: EXPERIMENTAL
Intervention: Vaccination (SARS-CoV-2 vaccine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (unvaccinated patients with post-acute COVID-19)
Number of subjects: 20
Study: 37243336

Group type: EXPERIMENTAL
Intervention: Temsirolimus (15 mg/m weekly)
Number of subjects: 10
Study: 37243345

Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg PO BID (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 40
Study: 37243342

Group type: EXPERIMENTAL
Intervention: Stigma-related variables
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Affirming healthcare provision
Number of subjects: 637
Study: 37243355

Group type: EXPERIMENTAL
Intervention: Cox regression models for composite time-to-event endpoints with component-wise censoring
Number of subjects: 0
Study: 37243446

Group type: EXPERIMENTAL
Intervention: Liver transplantation
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Canonical metabolic markers (serum methylmalonic acid and propionylcarnitine)
Number of subjects: 144
Study: 37243560

Group type: EXPERIMENTAL
Intervention: Differential stimulation of the NAc-ALIC
Number of subjects: 13
Study: 37243712

Group type: EXPERIMENTAL
Intervention: LL2643 quantitative polymerase chain reaction (qPCR)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Detection of LL2643 in plasma-derived circulating cell-free DNA (ccfDNA)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Detection of LL2643 ccfDNA post-treatment with diethylcarbamazine (DEC)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Detection of LL2643 in urine
Number of subjects: 53
Study: 37243941

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) defined as an apnea hypopnea index ≥ 15 events/h
Number of subjects: 1927
Study: 37243954

Group type: EXPERIMENTAL
Intervention: Incremental increases in positive end-expiratory pressure (PEEP) to a maximum of 15 cmH2O
Number of subjects: 0
Study: 37244205

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0
Study: 37244266

Group type: EXPERIMENTAL
Intervention: Befotertinib (75-100 mg once daily)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Icotinib (125 mg three times per day)
Number of subjects: 362
Study: 37244360

Group type: EXPERIMENTAL
Intervention: Concomitant boosts to 74 Gy total over 30 fractions
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard 60 Gy radiation
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Proton therapy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Carboplatin-paclitaxel
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Upper quartile decrease in SUVmean (>39.7%)
Number of subjects: 45
Study: 37244366

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 0